Eli Lilly stock last trades at USD 1,186.07 on September 28, 2026
Published on 09/28/2026 at 21:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Eli Lilly and Company shares last traded at USD 1,186.07 on the New York Stock Exchange on September 28, 2026, at 7:42:41 p.m. UTC. The stock was up 0.22 percent, or USD 2.61, from the previous session.
Trading session
The quote was recorded while regular trading was open. The company’s primary listing is identified as NYSE: LLY in Lilly’s investor-relations materials.
Cardiometabolic data at EASD
In a September 15 release, Eli Lilly and Company said it would present data on Foundayo, retatrutide and eloraTZP at the European Association for the Study of Diabetes’ annual meeting in Milan from September 28 to October 2. Lilly said the program includes Phase 3 results for investigational retatrutide, Phase 3 results for Foundayo and Phase 2 results for investigational eloraTZP.
The same release said Lilly’s September 30 retatrutide symposium would include TRIUMPH-2 results in which participants with obesity or overweight and type 2 diabetes lost up to an average of 49.6 pounds, or 20.8 percent, and lowered A1C by up to an average of 1.6 percent at 80 weeks. The figures were presented by Lilly as study results.
Recent acquisition completed
In a separate September 11 release, Eli Lilly and Company announced the completion of its acquisition of AtaiBeckley Inc. Lilly described AtaiBeckley as a clinical-stage biopharmaceutical company developing rapid-acting neuroplastogens, including BPL-003 for treatment-resistant depression.
